Key facts
- Volastra’s last known valuation is $150.6M (Sep 2025).
- It has raised $149.1M; the latest was Later Stage VC ($30.1M) in Sep 2025.
- Notable investors include B Capital Group, ARCH Venture Partners, Emerson Collective, Catalio Capital Management, Polaris Partners — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Volastra
- ·The full record, as it builds
Funding rounds
No funding rounds for Volastra are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Volastra
Operator of a drug discovery and therapeutics company intended to treat and prevent the formation of metastatic disease. The company combines bioinformatics and proprietary imaging techniques to identify which cancers are more likely to spread, enabling healthcare professionals to identify targets, select the appropriate patients for therapy effectively, and improve patient outcomes.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 41
- Website
- volastratx.com/
- Ownership
- Privately Held (backing)
Volastra doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Volastra shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Volastra in its N-PORT filings yet. We sweep new filings monthly.